Jason <span>B.</span> Brayer
Researcher

Jason B. Brayer

Overview

Discipline

    • Malignant Hematology
    • Immunology
    • Immunology

Education & Training

    • University of South Florida, MD
    • University of Florida, PhD - Medical Science (Immunology)
    • La Jolla Institute of Allergy & Immunology, Fellow - Immunology
    • H. Lee Moffitt Cancer Center and Research Institute, Fellow
    • University of South Florida, Resident - Internal Medicine
    • H. Lee Moffit Cancer Center and Research Institute, Fellow - Hematology/Oncology
Research

My research interests include:• Exploring the therapeutic potential of HDAC11 inhibitors in the treatment of multiple myeloma.• Exploring the potential for selective HDAC11 inhibitors to enhance T cell responses in the context of immunotherapy, including vaccine-based and cellular adoptive therapeutic approaches.• Defining the functional significance of the interaction between HDAC11 and IRF4 and its impact as a regulator of CD8 T cell function.• Defining the functional significance of the interaction between HDAC11 and IRF4 as it relates to myeloma cell development and survival.

Publications

  • Brayer J, Baz R. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol. 2017 Jul;8(7):209-220. Pubmedid: 28694935. Pmcid: PMC5495505.
  • Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015 Jul;90(7):602-607. Pubmedid: 25802083. Pmcid: PMC4617516.
  • Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein-Barr viremia. Leuk Lymphoma. 2014 Nov;55(11):2660-2662. Pubmedid: 24528217.
  • Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. J Immunother. 2014 Apr;37(3):187-191. Pubmedid: 24598453.
  • Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett. 2010 Jul;131(2):126-130. Pubmedid: 20346983. Pmcid: PMC2906450.
  • Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett. 2009 Aug;125(2):114-118. Pubmedid: 19555720. Pmcid: PMC2758552.
  • Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006 Apr;107(7):2871-2878. Pubmedid: 16339406. Pmcid: PMC1895389.
  • Ghansah T, Paraiso K, Highfill S, Desponts C, May S, McIntosh J, Wang J, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr W. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol. 2004 Dec;173(12):7324-7330. Pubmedid: 15585856.
  • Rodriguez P, Quiceno D, Zabaleta J, Ortiz B, Zea A, Piazuelo M, Delgado A, Correa P, Brayer J, Sotomayor E, Antonia S, Ochoa J, Ochoa A. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004 Aug;64(16):5839-5849. Pubmedid: 15313928.
  • Cheng F, Wang H, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr W, TakedaK, Akira S, Schoenberger S, Yu H, Jove R, Sotomayor E. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003 Sep;19(3):425-436. Pubmedid: 14499117.
  • Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello I, Levitsky H, Sotomayor E. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 2003;63(24):9007-9015. Pubmedid: 14695219.